Killer dendritic cells: IKDC and the others

Current Opinion in Immunology

Volumn 20, Issue 5, 2008, Pages 558-565

  Bonmort, Mathieu ^a,b   Dalod, Marc ^a,c,d   Mignot, Grégoire ^a,b   Ullrich, Evelyn ^a,b   Chaput, Nathalie ^a,b   Zitvogel, Laurence ^a,b,e  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^d CNRS   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD103 ANTIGEN; CD123 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD200 ANTIGEN; CD3 ANTIGEN; CD32 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANZYME; GRANZYME A; HIGH MOBILITY GROUP B1 PROTEIN; IMIQUIMOD; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 2 RECEPTOR GAMMA; LYMPHOTOXIN; LYMPHOTOXIN ALPHA BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NITRIC OXIDE; PERFORIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTATION; BASAL CELL CARCINOMA; BONE MARROW CELL; CANCER CONTROL; DENDRITIC CELL; HUMAN; IN VITRO STUDY; INTERFERON PRODUCING KILLER DENDRITIC CELL; KILLER CELL; LYMPHOID CELL; LYMPHOKINE ACTIVATED KILLER CELL; NONHUMAN; REVIEW; TUMOR CELL; TUMOR GROWTH;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; INTERFERONS; INTERLEUKIN-15; KILLER CELLS, NATURAL; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTORS;

EID: 50549099693     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2008.04.006     Document Type: Review

References (49)

1. Zitvogel L., Apetoh L., Ghiringhelli F., and Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8 (2008) 59-73
2. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., and Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 (2007) 903-907
3. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13 (2007) 1050-1059. The first demonstration of a contribution of the immune system to the tumoricidal activity of chemotherapy and radiotherapy through the binding of tumor-secreted HMGB1 to TLR4.
4. Milas L., Wike J., Hunter N., Volpe J., and Basic I. Macrophage content of murine sarcomas and carcinomas: associations with tumor growth parameters and tumor radiocurability. Cancer Res 47 (1987) 1069-1075
5. Boissonnas A., Fetler L., Zeelenberg I.S., Hugues S., and Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med 204 (2007) 345-356
6. Bonnotte B., Larmonier N., Favre N., Fromentin A., Moutet M., Martin M., Gurbuxani S., Solary E., Chauffert B., and Martin F. Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J Immunol 167 (2001) 5077-5083
7. Stary G., Bangert C., Tauber M., Strohal R., Kopp T., and Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 204 (2007) 1441-1451. A master piece showing the capacity of topical TLR7 agonists to mediate the recruitment and differentiation of human myeloid and plasmacytoid DC into killer cells in cancer.
8. Wesa A.K., and Storkus W.J. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. Cell Death Differ 15 (2008) 51-57. This is an exhaustive review describing most of the current literature on natural and induced killer DC in mice and humans.
9. ••].
10. ••].
11. ••], this manuscript demonstrates the role of effector memory T lymphocytes in the natural immunosurveillance of colon cancer and the potential of the follow up of this parameter for the staging and treatment of patients.
12. Zhang J.K., Li J., Chen H.B., Sun J.L., Qu Y.J., and Lu J.J. Antitumor activities of human dendritic cells derived from peripheral and cord blood. World J Gastroenterol 8 (2002) 87-90
13. Evans R. Macrophages and neoplasms: new insights and their implication in tumor immunobiology. Cancer Metastasis Rev 1 (1982) 227-239
14. Simonetti O., Goteri G., Lucarini G., Rubini C., Stramazzotti D., Lo Muzio L., Biagini G., and Offidani A. In melanoma changes of immature and mature dendritic cell expression correlate with tumor thickness: an immunohistochemical study. Int J Immunopathol Pharmacol 20 (2007) 325-333
15. Srivastava R.M., Varalakshmi C., and Khar A. Cross-linking a mAb to NKR-P2/NKG2D on dendritic cells induces their activation and maturation leading to enhanced anti-tumor immune response. Int Immunol 19 (2007) 591-607
16. Fanger N.A., Maliszewski C.R., Schooley K., and Griffith T.S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 190 (1999) 1155-1164
17. Shibaki A., and Katz S.I. Activation through CD40 ligation induces functional Fas ligand expression by Langerhans cells. Eur J Immunol 31 (2001) 3006-3015
18. Huang J., Tatsumi T., Pizzoferrato E., Vujanovic N., and Storkus W.J. Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation. Cancer Res 65 (2005) 8461-8470
19. •].
20. •], this paper interestingly highlights a subset of circulating DC with an 'inflammatory' profile.
21. •].
22. •], this paper is an important demonstration of the capacity of circulating human DC to exhibit a killer activity through the TNF subfamily members.
23. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., Castedo M., Mignot G., Panaretakis T., Casares N., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13 (2007) 54-61
24. Ito N., DeMarco R.A., Mailliard R.B., Han J., Rabinowich H., Kalinski P., Stolz D.B., Zeh III H.J., and Lotze M.T. Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol 81 (2007) 75-83
25. Ullrich E., Bonmort M., Mignot G., Jacobs B., Bosisio D., Sozzani S., Jalil A., Louache F., Bulanova E., Geissman F., et al. Trans-presentation of interleukin-15 dictates IKDC effector functions. Part I. J Immunol 180 (2008) 7887-7897
26. Ullrich E., Chaput N., and Zitvogel L. Killer dendritic cells and their potential role in immunotherapy. Horm Metab Res 40 (2008) 75-81
27. ••].
28. ••].
29. ••], this paper is a pioneering work unraveling the potential of a subset of rat DC to exert a killing activity against a variety of targets and to engulf dying cells.
30. Alli R., Savithri B., Das S., Varalakshmi C., Rangaraj N., and Khar A. Involvement of NKR-P2/NKG2D in DC-mediated killing of tumor targets: indicative of a common, innate, target-recognition paradigm?. Eur J Immunol 34 (2004) 1119-1126
31. •].
32. •], this paper interestingly demonstrates the capacity of M-DC8 cells to exhibit ADCC and TNFα-mediated killing.
33. + dendritic cell capable of killing and mediating tolerogenic effects in a diabetes model.
34. Chaudhry U.I., Kingham T.P., Plitas G., Katz S.C., Raab J.R., and DeMatteo R.P. Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth. Cancer Res 66 (2006) 10497-10504
35. Pillarisetty V.G., Katz S.C., Bleier J.I., Shah A.B., and Dematteo R.P. Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN-gamma via autocrine IL-12. J Immunol 174 (2005) 2612-2618
36. Chaudhry U.I., Katz S.C., Kingham T.P., Pillarisetty V.G., Raab J.R., Shah A.B., and DeMatteo R.P. In vivo overexpression of Flt3 ligand expands and activates murine spleen natural killer dendritic cells. FASEB J 20 (2006) 982-984
37. •].
38. + cells to mediate both killing and/or antigen-presenting functions and of its unique role in keeping in check tumor progression.
39. •].
40. •].
41. •], and shows that B220, CD11c, and CD11b can be acquired during activation of bona fide NK cells.
42. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med 195 (2002) F9-F14
43. Robbins S.H., Walzer T., Dembele D., Thibault C., Defays A., Bessou G., Xu H., Vivier E., Sellars M., Pierre P., et al. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol 9 (2008) R17
44. Mignot G., Ullrich E., Bonmort M., Ménard C., Apetoh L., Taieb J., Bosisio D., Sozzani S., Ferrantini M., Schmitz J., et al. The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. Part II. J Immunol 180 (2008) 6477-6483
45. Hanna J., Gonen-Gross T., Fitchett J., Rowe T., Daniels M., Arnon T.I., Gazit R., Joseph A., Schjetne K.W., Steinle A., et al. Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest 114 (2004) 1612-1623
46. Roncarolo M.G., Bigler M., Haanen J.B., Yssel H., Bacchetta R., de Vries J.E., and Spits H. Natural killer cell clones can efficiently process and present protein antigens. J Immunol 147 (1991) 781-787
47. Spits H., and Lanier L.L. Natural killer or dendritic: what's in a name?. Immunity 26 (2007) 11-16
48. Yang R., Xu D., Zhang A., and Gruber A. Immature dendritic cells kill ovarian carcinoma cells by a FAS/FASL pathway, enabling them to sensitize tumor-specific CTLs. Int J Cancer 94 (2001) 407-413
49. Hardy A.W., Graham D.R., Shearer G.M., and Herbeuval J.P. HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha. Proc Natl Acad Sci U S A 104 (2007) 17453-17458